Quest Diagnostics’ Post

Johnson & Johnson Concludes Acquisition Of Shockwave Medical Johnson & Johnson has announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion. The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17 in 2025. In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ. Joaquin Duato Tim Schmid #johnsonandjohnson #johnsonandjohnsonnews #acquisition #shockwavemedical

M&A: Alcon Acquires BELKIN Vision for $81M - HIT Consultant #MergersAndAcquisitions: Alcon Acquires BELKIN Vision for $81M In a recent development, Alcon has acquired BELKIN Vision for $81M, expanding its presence in the healthcare IT market. The acquisition aims to enhance Alcon's portfolio of vision care solutions and strengthen its position in the industry. #StrategicPartnership: Alcon's Acquisition Strategy Alcon's acquisition of BELKIN Vision is part of its strategic partnership approach to grow its business and offer innovative solutions to customers. By joining forces with BELKIN Vision, Alcon aims to leverage their expertise and technology to drive growth and improve patient outcomes. #ImpactOnHealthcareIT: Enhanced Vision Care Solutions The acquisition ai.mediformatica.com #vision #acquisition #technology #this #integration #market #physicians #eyecare #management #outcomes #patientcare #patients #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3xD12Mn)

Haemonetics Completes Acquisition of OpSens - https://lnkd.in/gqhrGEKd Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Haemonetics, OpSens Medical #medicalequipmentsupplier #acquisition

Is J&J's $13.1 billion Shockwave acquisition a game-changer? 🤔 Johnson & Johnson's $13.1 billion acquisition of Shockwave Medical has sent shockwaves through the medical industry, raising questions about its potential to revolutionise cardiovascular care. With Shockwave's expertise in intravascular lithotripsy (IVL) devices, J&J will be in a better spot to enter high-growth markets like coronary artery disease (CAD) and peripheral artery disease (PAD). With both companies' boards greenlighting the deal, J&J anticipates finalisation by mid-2024, aiming to leverage operational synergies and fuel growth through strategic investments. Despite regulatory hurdles, J&J remains bullish on the deal's timeline, with CEO Joaquin Duato expressing confidence in meeting targets. Needham analysts view the acquisition favourably, citing minimal product overlap and dismissing the likelihood of competing bids. This acquisition follows J&J's previous foray into the MedTech arena, reinforcing its commitment to cardiovascular innovation and positioning Shockwave as a key player within its MedTech division. Dive deeper into this topic by clicking the link below. https://lnkd.in/g6faRxrU

Quest Diagnostics and OhioHealth announced a definitive agreement for Quest to acquire select assets of OhioHealth’s outreach laboratory services business. The transaction will broaden access to cost-effective and innovative laboratory services in Ohio. After the acquisition’s close, providers and patients will benefit from access to Quest’s industry-leading test menu, network of patient service sites throughout the state, broad health plan coverage, and lower out-of-pocket costs for many services. Read More: https://lnkd.in/dpkFMTuq Christopher Clinton, President, OhioHealth Regional Market and former Vice President, Shared Services, Juanita Swickard, Interim Vice President, Shared Services, OhioHealth. & Jim Davis Chairman, CEO and President, Quest Diagnostics commented on the acquisition #mededgemea #QuestDiagnostics #ohiohealth #HealthcareAcquisition #labservices #MedicalTesting #healthcarenews #HealthInnovation #diagnostics #HealthcarePartnership #laboutreach

23+ years after Baxter CardioVascular Group spin-off from Baxter to form #EdwardsLifesciences, that happened to be one of the most successful #spinoffs in #medtechecosystem year to date, #EW has announced another spin off today of Critical Care organization next year, something that was more or less anticipated from #corporatestrategy experts in medtech . This bold move will help #EW to sharpen its focus on #StructuralHeartDisease, further advance #ValveTherapies and treatments and integrate a new pillar in #HeartFailure and more specifically #InterventionalHF through internal program and focused potential pre-revenue #acquisitions and investments leveraging at the same time the existing world class financials. At the same time, #CriticalCare organization has a unique opportunity to build on its legacy as a ~$1 billion global market leader and enables increased focus and flexibility to improve the quality of care for millions of patients around the world and optimizes the return to the shareholders of the newCo through organic growth, potential acquisitions, and strategic collaborations. Exciting times ahead for #EW and the new spin-off company. Fasten your seat belts and the firing of all cylinders has just initiated!! #innovation #medtechstrategy

Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.” Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry. Shockwave’s differentiated solutions and robust pipeline represent an exciting opportunity for Johnson & Johnson MedTech to bring more innovations to patients in one of the largest areas of unmet medical need. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.” This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (Biosense Webster) to make it a category leader in four of the largest and highest-growth medtech markets within cardiovascular intervention. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1 billion. The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech. Johnson & Johnson expects the transaction to be accretive to operating margin, but considering the impact of financing costs, is expected to dilute adjusted earnings per share by approximately $0.10 in 2024 and approximately $0.17 in 2025. In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ. #intravascularlithotripsy #cardiovascularintervention #acquisition #Shockwave #JohnsonandJohnson #JnJ #MedTech #JNJMedTech #JNJMedTechProud 

OPTIMISM growing and growing AND HERE IS MORE OPTIMISM for your weekend! great quote too: "Cleveland is a Land of Big Ideas and Bold Ventures where we make things that matter. - Baiju Shah VENTURE capital is OPTIMISTIC with regard to Cleveland! KEEP YOUR EYES OPEN! for MOREin24! #cleveland #optimism #investmentopportunity

🌟 Advancing Healthcare: Johnson & Johnson's Strategic Acquisitions 🌟 Johnson & Johnson, a global leader in healthcare, has continually expanded its horizons through strategic acquisitions, making impactful investments in the future of health. Let's take a moment to appreciate these significant milestones, including their respective costs: 1. **Janssen Pharmaceutica (1961, Approx. $441 million)**: A historic acquisition that solidified J&J's presence in the pharmaceutical industry, bringing a rich portfolio of innovative drugs. 2. **Ortho-McNeil (1997, Approx. $1.9 billion)**: This acquisition significantly strengthened J&J's capabilities in pharmaceutical research and development. 3. **DePuy (1998, Approx. $3.5 billion)**: A pivotal move that bolstered J&J's presence in orthopedics, providing innovative solutions for joint reconstruction, spinal care, and sports medicine. 4. **Cordis Corporation (1996, Approx. $1.8 billion)**: This strategic acquisition expanded J&J's offerings in cardiovascular care, bringing in innovative technologies for interventional medicine. 5. **Synthes (2012, Approx. $21.3 billion)**: A landmark acquisition that solidified J&J's position in orthopedics and neurosurgery, providing a comprehensive portfolio of surgical solutions. 6. **Actelion (2017, Approx. $30 billion)**: This strategic acquisition reinforced J&J's leadership in pulmonary hypertension, adding a rich pipeline of innovative therapies. 7. **Abbott Medical Optics (2017, Approx. $4.3 billion)**: This acquisition expanded J&J's offerings in ophthalmic surgery, providing advanced technologies for cataract and refractive surgery. 8. **Momenta Pharmaceuticals (2020, Approx. $6.5 billion)**: Acquiring Momenta Pharmaceuticals bolstered J&J's capabilities in autoimmune diseases, adding innovative therapies to address unmet medical needs. These acquisitions, totaling approximately $69.5 billion, showcase Johnson & Johnson's steadfast dedication to advancing healthcare and improving the well-being of people around the world. They've not only enriched the company's offerings but have also contributed to shaping the future of healthcare. 🌐⚕️ #JNJ #HealthcareInnovation #ExpandingPossibilities #MergersAndAcquisitions #BusinessIntegration #StrategicPartnerships #AcquisitionStrategy #DealMaking #CorporateDevelopment #MarketExpansion #BusinessGrowth #DealMakers #IntegrationPlanning #SynergyRealized #MandAInsights #DealStrategy #FinancialTransactions #BusinessSynergies #IPO

Johnson & Johnson has announced its acquired Shockwave Medical. Under the terms of the deal, Johnson & Johnson will purchase all outstanding shares of Shockwave for $335.00 per share in cash, totaling approximately $13.1 billion including cash acquired. The transaction, approved by both companies' boards of directors, aims to bolster Johnson & Johnson's presence in cardiovascular intervention and tap into higher-growth markets. With this acquisition, Johnson & Johnson's medtech cardiovascular portfolio will expand into coronary artery disease (CAD) and peripheral artery disease (PAD). This move follows Johnson & Johnson MedTech's recent acquisitions of Abiomed, a heart recovery leader, and Laminar, specializing in left atrial appendage elimination for patients with non-valvular atrial fibrillation (AF). Shockwave Medical is recognized for its intravascular lithotripsy (IVL) technology, which treats calcified CAD and PAD through minimally invasive, catheter-based procedures, mitigating risks like reduced blood flow or heart attacks.